請輸入關鍵字:

熱門搜尋:

Philip Morris International Announces U.S. Food and Drug Administration Authorization For Sale of IQOS in the United States

日期:2019年5月6日 上午9:44

NEW YORK--()--The U.S. Food and Drug Administration (FDA) today confirmed that IQOS, Philip Morris International’s electrically heated tobacco system, is appropriate for the protection of public health and has authorized it for sale in the United States. FDA’s decision follows its comprehensive assessment of PMI’s premarket tobacco product applications (PMTAs) filed with the Agency in 2017.

Unlike cigarettes, the IQOS system heats — but does not burn — tobacco. It is the first electrically heated tobacco product to qualify for sale in the U.S. pursuant to the 2009 law that empowers FDA to regulate tobacco products, including through oversight of innovative products.

Commenting on the FDA’s announcement, André Calantzopoulos, PMI’s Chief Executive Officer, said:

“The FDA’s decision to authorize IQOS in the U.S. is an important step forward for the approximately 40 million American men and women who smoke. Some will quit. Most won’t, and for them IQOS offers a smoke-free alternative to continued smoking. In just two years, 7.3 million people around the world have abandoned cigarettes and switched completely to IQOS. Today’s decision by FDA makes this opportunity available to American adult smokers. All of us at PMI are determined to replace cigarettes with smoke-free alternatives that combine sophisticated technology and intensive scientific validation. FDA’s announcement is a historic milestone.”

He added, “The order sets out clear commercialization guidelines, including marketing requirements, that maximize the opportunity for adults to switch from cigarettes, while minimizing unintended use. We fully support this objective. FDA has set a high standard and we look forward to working with them to implement the order so that IQOS is reaching the right audience—current adult smokers.

PMI will bring IQOS to the U.S. market through an exclusive license with Altria Group, Inc., whose subsidiary Philip Morris USA has the market expertise and infrastructure to ensure a successful launch. PM USA is ready to deploy its initial lead market plans for IQOS.

PMI submitted a comprehensive body of scientific evidence in support of the PMTAs and of the parallel applications for IQOS as a “Modified Risk Tobacco Product”, which FDA continues to review.

Note to Editor

PMP SA submitted PMTA applications for IQOS and three HeatStick variants: Marlboro HeatSticks, Marlboro Smooth Menthol HeatSticks; and Marlboro Fresh Menthol HeatSticks.

Philip Morris International: Delivering a Smoke-Free Future

Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company and its shareholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, smoke-free products and associated electronic devices and accessories, and other nicotine-containing products in markets outside the U.S. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. PMI's smoke-free IQOS product portfolio includes heat-not-burn and nicotine-containing vapor products. As of March 31, 2019, PMI estimates that approximately 7.3 million adult smokers around the world have already stopped smoking and switched to PMI’s heat-not-burn product, which is currently available for sale in 47 markets in key cities or nationwide under the IQOS brand. For more information, please visit www.pmi.com and www.pmiscience.com.

 

Philip Morris International Announces U.S. Food and Drug Administration Authorization For Sale of IQOS in the United States

Contacts

Corey Henry
Philip Morris International Media Office
T. +1 (202) 679 7296
E. corey.henry@pmi.com

財華網所刊載內容之知識產權為財華網及相關權利人專屬所有或持有。未經許可,禁止進行轉載、摘編、複製及建立鏡像等任何使用。

如有意願轉載,請發郵件至content@finet.com.hk,獲得書面確認及授權後,方可轉載。

下載財華財經APP,把握投資先機
https://www.finet.com.cn/app

更多精彩内容,請點擊:
財華網(https://www.finet.hk/)
財華智庫網(https://www.finet.com.cn)
現代電視FINTV(https://www.fintv.hk)

相關文章

5月2日
新西蘭旅遊局與騰訊簽署合作備忘錄 共同促進「2019中新旅遊年」遊客增長
5月2日
長城匯理引入獨角獸九次方作為戰略投資人,發力銀保證金大數據領域
4月30日
Murray Energy Corporation在Mission煤礦破產之際完成對Oak Grove、Seminole Alabama和Maple Eagle Mining Complexes的收購
4月30日
由日本農林水產省資助、針對非日本籍廚師的日本料理培訓計畫現招募真心希望前往日本學習日本料理的人士
4月30日
穆迪詳細介紹全球企業社會責任工作成果
4月30日
MSCI任命Linda S. Huber為財務長
4月30日
AerSale將攜手Universal Avionics為Airbus 320飛機上的ClearVisionTM增強型飛行目視系統開發STC
4月30日
The We Company宣佈就擬議首次公開發行機密遞交登記聲明草案
4月30日
tHIS 2019擴大滬杭兩地的展覽規模以描繪健康科技的未來
4月30日
Masimo宣布首款用於 Root®患者監護與互聯總機的協力廠商Masimo Open Connect®模組獲得CE標記

視頻

快訊

20:03
海南封關落地!板塊投資機遇幾何?
19:46
機器人板塊集體走強,人形機器人從「炫技」邁向「上崗」
17:34
國家網信辦會同中國證監會深入整治涉資本市場網上虛假不實信息
17:28
碩奧國際(02336.HK):馮櫓銘獲任董事會主席
17:19
復宏漢霖(02696.HK)HLX18治療多種實體瘤的1期臨床試驗申請獲美FDA批准
17:11
國家外匯局:11月銀行結匯2095億美元 售匯1938億美元
17:04
中國白銀集團(00815.HK)認購協議已部分完成
16:50
美高梅中國(02282.HK):馮小峰獲任首席執行官
16:39
超大現代(00682.HK)完成配售3295萬股 淨籌約719萬港元
16:32
香港10月批出六份建築圖則